Vector Science and Therapeutics Hires RedChip for Investor Relations
Mequon-based Vector Science and Therapeutics Corp. has signed a twelve-month agreement with RedChip Companies to boost its institutional outreach. The deal, effective August 24, 2026, aims to refine the company's investor collateral and communication strategy as it seeks to broaden its presence among analysts and media outlets.
Under the terms of the agreement, Vector will pay the Florida-based firm US$8,500 monthly. RedChip, led by CEO Dave Gentry, will manage investor decks and website disclosures while facilitating direct engagement with portfolio managers and investment advisors. The engagement remains subject to final approval by the TSX Venture Exchange.
To align incentives, the company has granted RedChip 150,000 stock options at a price of C$1.80 per share. These options, which expire in August 2029, will vest quarterly throughout the duration of the contract. Vector, which trades under the ticker PAIN, develops biomechanical and localized drug delivery platforms and currently maintains an arms-length relationship with its new IR partner.
Comments (0)
No comments yet. Be the first!